Registry of Atrial Fibrillation and Embolic Risk in Mexico
NCT02334852
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Patients with documented diagnosis of AF in the last six months by 12-lead electrocardiogram, rhythm strip, or Holter monitoring, pacemaker minimum 30 seconds (with or without treatment and regardless of rhythm during enrollment)
- Patients presenting AF (diagnosed by standard ECG or Holter monitoring) at baseline
- Patients should be eligible for treatment with oral anticoagulant thromboprophylaxis
- Patients with at least 1 risk factor for thromboembolism (CVE or outside the CNS) according to CHA2DS2VASc
- AF of transient causes (thyrotoxicosis, alcohol intoxication, myocardial infarction
(MI) acute phase, pericarditis, myocarditis, electrocution, pulmonary embolism or
other lung disease, electrolyte or metabolic disorder,etc).
- AF onset in immediate postoperative or 3 months in cardiac surgery
- Terminal illness
- Mental Inability to take anticoagulants
- Inability to fulfill the follow-up visits
- Programming for ablation of pulmonary veins
- Pregnant or lactating women
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Groningen,
- Groningen,
- Haarlem,
- Leeuwarden,
- Maastricht,
- Nijmegen,
- Zaandam,
- Zwolle,
- Rochester, Minnesota
- Minato-ku, Tokyo
- Calgary, Alberta
Descriptive Information | ||||
---|---|---|---|---|
Brief Title | Registry of Atrial Fibrillation and Embolic Risk in Mexico | |||
Official Title | Registry of Atrial Fibrillation and Embolic Risk in Mexico | |||
Brief Summary | The AF is the most common arrhythmia in clinical practice affecting 1-2% of the general population. It is the most common cause of cerebrovascular events (CVE), responsible for 25% of all ischemic strokes and 50% of cardioembolic strokes. The CARMEN-AF registry is planned to be the first registry of non-valvular AF in Mexico with national representation, planning and specific objectives for publications. Follow-up period of two years is planned. | |||
Detailed Description | The CARMEN-AF registry intends to achieve a national sample of non-valvular AF in male and female patients older than 18 years through the participation of every state of Mexico. Thus, a wide geographical distribution will allow comparing health care quality between different geographical areas in which the patients are attended (Northwest, North, Center, Mexico City, East and Southeast). Besides, to guarantee this national representation, the principle health institutions are planned to participate, the public and the private ones. Primary objectives: To know the current state of thromboprophylaxis in non-valvular Atrial Fibrillation (AF) in Mexico. To evaluate the therapeutic behavior according to the Clinical Practice Guidelines (CPG) at baseline and one year follow-up, with an educational strategy to increase the adherence. Secondary objectives: To identify the characteristics of oral anticoagulants current use in Mexico. To analyze the efficiency of anticoagulation with vitamin K antagonists and the new oral anticoagulants, at baseline and one year follow-up. Descriptive statistics: For each group of variables the following descriptive statistics will be obtained: In continuous variables: mean, standard deviation (SD), standard error, confidence interval (CI) 95%, minimum, percentile 25, median, percentile75, maximum, n and number of lost data. In categorical variables: % from total column, n in each category. Lost data will be treated as a new category. Ethical aspects: Every investigator should fulfil the study according with the principles of the Helsinki declaration. Copies of the Helsinki Declaration and its subsequent amendments will be provided under specific request or can be obtained through the World Medical Association website (http://www.wma.net/en/30publications /10policies/b3/index.html). The study should be developed in accordance with the protocol and the procedures that ensure the standards of Good Clinical Practice (GCP) compliance (1996). The study will be conducted in accordance with the guidelines for Good Epidemiological Practice. Risk-benefit assessment for the research subjects: Patients included in the study are not subject to experimental considerations. Information sheet and informed consent form: As this study represents a longitudinal observational registry that does not imply therapeutic change, no informed consent form is contemplated. | |||
Study Type | Observational [Patient Registry] | |||
Study Design | Observational Model: Cohort Time Perspective: Prospective | |||
Target Follow-Up Duration | 2 Years | |||
Biospecimen | Not Provided | |||
Sampling Method | Probability Sample | |||
Study Population | Patients with documented diagnosis of AF in the last six months | |||
Condition | Atrial Fibrillation | |||
Intervention | Not Provided | |||
Study Groups/Cohorts | Not Provided | |||
Publications * | Márquez MF, Baños-González MA, Guevara-Valdivia ME, Vázquez-Acosta J, de Los Ríos Ibarra MO, Aguilar-Linares JA, Jiménez-Cruz M, Matadamas-Hernández N, Camacho-Casillas R, Magaña-Magaña R, Rojel-Martínez U, Alcocer-Gamba MA, Lara-Vaca S, Rodríguez-Reyes H, Islava-Gálvez MA, Betancourt-Hernández LE, Reyes-Reyes N, Beltrán-Gámez ME, Cantú-Brito C, Baños-Velasco AZ, Del Rivero Morfin PJ, González-Hermosillo JA. Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry. Glob Heart. 2020 Apr 10;15(1):32. doi: 10.5334/gh.767. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status | Completed | |||
Actual Enrollment | 1200 | |||
Original Estimated Enrollment | Same as current | |||
Actual Study Completion Date | March 2017 | |||
Actual Primary Completion Date | December 2016 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender |
| |||
Ages | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | Not Provided | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT02334852 | |||
Other Study ID Numbers | CARMEN | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | Registro de Fibrilación Auricular y Riesgo Embólico en México | |||
Study Sponsor | Registro de Fibrilación Auricular y Riesgo Embólico en México | |||
Collaborators |
| |||
Investigators |
| |||
PRS Account | Registro de Fibrilación Auricular y Riesgo Embólico en México | |||
Verification Date | April 2017 |